Drug Combination Details
| General Information of the Combination (ID: C54031) | |||||
|---|---|---|---|---|---|
| Name | Delphinidin NP Info | + | 3-bromopyruvate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | PEO1 | CVCL_2686 | BRCA2 syndrome | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Delphinidin increases the sensitivity of ovarian cancer cell lines to 3-bromopyruvate. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-Bromopyruvate. Int J Mol Sci. 2021 Jan 12;22(2):709. | |||
